Skip to main content
Figure 3 | BMC Cancer

Figure 3

From: Gonadotropin-releasing hormone type II (GnRH-II) agonist regulates the invasiveness of endometrial cancer cells through the GnRH-I receptor and mitogen-activated protein kinase (MAPK)-dependent activation of matrix metalloproteinase (MMP)-2

Figure 3

Effects of human GnRH-I receptor siRNA (si-GnRH-IR) transfection on endometrial cancer cells. (A) The transfection efficiency of siRNA in endometrial cancer cells. (B) GnRH-I receptor levels were monitored by immunoblot assays. The endometrial cancer cells were transfected with human si-GnRH-IR or scrambled siRNA (si-Ctrl) for one day with Lipofectamine RNAiMAX. (C) The effects of si-GnRH-IR transfection on the GnRH-II-induced cell migration. The cells were transfected with si-GnRH-IR and treated with GnRH-II (1 μM) for 24 h. The cell motility was assessed with the migration assay. The results are expressed as the mean ± SEM of three independent experiments. (*p<0.05, versus control; #p<0.05, versus GnRH-II). The effects of si-GnRH-IR transfection on GnRH-II-induced cell invasion. The cells were transfected with si-GnRH-IR and treated with GnRH-II (1 μM) for 48 h. The cell motility was assessed with the invasion assay. The results are expressed as the mean ± SEM of three independent experiments. (*p<0.05, versus control; #p<0.05, versus GnRH- II).

Back to article page